Metformin as a Treatment for Antipsychotic Drug Side Effects: Special Focus on Women With Schizophrenia

American Journal of Psychiatry (Impact Factor: 13.56). 08/2012; 169(8):774-6. DOI: 10.1176/appi.ajp.2012.12050591
Source: PubMed
1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia has long been known to affect men and women somewhat differently. It has been shown that men have a higher incidence, a younger age of onset, more impaired functioning, and poorer response to treatment. Generally acknowledged risk factors such as season of birth, obstetric complications, head trauma and substance abuse affect males more than they do females. This paper examines other potential predictive factors, genetic and environmental, that have come to attention over the last five years and examines their relative gender risk. Recent findings pertinent to women with schizophrenia have emerged with respect to hormonal effects, antipsychotic metabolism and antipsychotic side effects. A new concept relative to outcome is recovery, which, thus far, shows no gender difference. The paper also addresses the needs of specific groups of women affected by schizophrenia – those in the early stages of illness, those who are pregnant, those who are mothers, and those who are in their postmenopausal years. Several new findings are advancing the field of women and schizophrenia.
    Neuropsychiatry 08/2013; 3(4):423-431. DOI:10.2217/npy.13.55
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psychiatric symptoms often manifest years before overt neurologic signs in patients with inherited neurodegenerative disease. The most frequently cited example of this phenomenon is the early onset of personality changes in "presymptomatic" Huntington patients. In some cases the changes in mood and cognition are even more debilitating than their neurologic symptoms. The goal of this article is to provide the neurologist with a concise primer that can be applied in a busy clinic or private practice.
    Neurologic Clinics 11/2013; 31(4):1121-44. DOI:10.1016/j.ncl.2013.04.016 · 1.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: NAFLD model rats were established and divided into NAFLD model (MG group), SIRT1 RNAi (SI group), blueberry juice (BJ group), blueberry juice + bifidobacteria (BJB group), blueberry juice + SIRT1 RNAi (BJSI group), and blueberry juice + bifidobacteria + SIRT1 RNAi groups (BJBSI group). A group with normal rats was a control group (CG). BJB group ameliorated NAFLD, which was better than BJ group (P < 0.05). The lipid accumulation was lower in CG, BJ, and BJB groups than that in MG, SI, BJSI, and BJBSI groups (P < 0.05). The levels of SIRT1 and PPAR-α were higher in CG, BJ, and BJB groups than those in MG, SI, BJSI, and BJBSI groups (P < 0.05). The levels of SREBP-1c were lower in CG, BJ, and BJB groups than those in MG, SI, BJSI, and BJBSI groups (P < 0.05). The biochemical indexes SOD, GSH, and HDL-c were improved from CG to BJB group (P < 0.05). Inversely, the levels of AST and ALT, TG, TC, LDL-c, and MDA were decreased from CG to BJB group (P < 0.05). These changes enhance antioxidative capability and biochemical index of rats. Blueberry juice and bifidobacteria improve NAFLD by activating SIRTI-mediating signaling pathway.
    Oxidative medicine and cellular longevity 11/2014; 2014:469059. DOI:10.1155/2014/469059 · 3.36 Impact Factor